Underactive bladder syndrome (UAB) is a chronic urological condition characterized by the bladder's inability to contract effectively or sustain a contraction long enough to completely empty during urination. As a result, individuals often experience prolonged urination, a weak urinary stream, hesitancy, straining to void, and a persistent sensation of incomplete bladder emptying. In some cases, urinary retention may occur, increasing the risk of recurrent urinary tract infections and bladder complications.
UAB can arise from multiple underlying causes, including age-related changes, nerve damage, diabetes, spinal cord injuries, pelvic surgery, or neurological disorders such as multiple sclerosis and Parkinson's disease. In many patients, weakened bladder muscle function, known as detrusor underactivity, is the primary physiological abnormality.
The condition can significantly affect quality of life, causing discomfort, sleep disturbances, social limitations, and emotional distress. Because its symptoms often overlap with other lower urinary tract disorders, accurate diagnosis typically requires a detailed medical history, physical examination, bladder function tests, and urodynamic studies.
Treatment strategies focus on improving bladder emptying and managing symptoms. These may include behavioral interventions, timed voiding, intermittent catheterization, medications, and, in some cases, neuromodulation therapies. Growing awareness and advances in diagnostic technologies are helping improve the recognition and management of underactive bladder syndrome, offering hope for better patient outcomes.

Underactive Bladder (UAB) Syndrome Market

Underactive Bladder Syndrome Market Infographic

Underactive Bladder Syndrome Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape